ABSTRACT
Factor V(FV) is a rare bleeding disorder that its incidence is one in a million. Patients with FV deficiency have typically mucosal bleeding and prolonged bleeding after an invasive procedure. There are no certain treatment modalities and there is no product of FV concentrates in the markets. The bleeding diathesis and protect the ovarian viability are a challenge as an opposite situation for treatment options and ovarian preservation after detorsion is controversial. We aimed to provide ovarian blood-stream,control bleeding and protect thromboembolism from the patient with all of our treatment in the light of literature and a few case reports.
ABSTRACT
Rare bleeding disorders (RBD) are autosomal recessive inherited diseases caused by one or more coagulation factor defects, including the deficiency of fibrinogen (FG), prothrombin, factor (F)V, Ⅶ, Ⅹ,Ⅺ, Ⅷ and so on. Due to the low prevalence of RBD, and lack of large-scale randomized controlled studies in the world, where are great challenges to clinicians in diagnosis and treatment of this series of diseases. Facing in the heterogeneity of clinical phenotype and laboratory characteristics, it is more necessary to strengthen the communication and cooperation between the clinical and laboratory, realizing comprehensive management.